ACE-031 (Ramatercept)

Comprehensive Research Analysis - Myostatin Inhibitor for Muscle Growth

Classification: Myostatin Inhibitor, Activin Receptor Type IIB Fusion Protein Alternative Names: Ramatercept, ActRIIB-IgG1 Fc, Myostatin Inhibitory Peptide 7 Chemical Formula: C₃₄₁₈H₅₁₈₈N₉₂₈O₁₀₆₂S₃₈ Molecular Weight: 77,489.82 g/mol (homodimeric form) CAS Number: 1621169-52-5 Protein Structure: 343 amino acids (ActRIIB extracellular domain + IgG1 Fc domain) Research Status: DISCONTINUED (May 2013) WADA Status: PROHIBITED (S4.3 - Metabolic Modulators)

ACE-031 development was PERMANENTLY DISCONTINUED in May 2013 due to safety concerns identified in clinical trials [1]. Despite promising muscle-building effects, the compound caused:

• Epistaxis (nosebleeds)
• Telangiectasias (dilated blood vessels near skin surface)
• Gum bleeding

These adverse events, while individually minor, prompted FDA and Health Canada regulatory review leading to termination of all clinical studies [2]. Acceleron Pharma and Shire concluded their collaboration and permanently halted the development program [1].

Current Status: Available only as research chemical through unregulated "black market" suppliers [3]. Not approved for human use by any regulatory authority.

Goal Relevance:

• Increase muscle mass and strength for individuals with muscle-wasting conditions like Duchenne muscular dystrophy.
• Enhance lean body mass for those seeking improved muscle definition and physical performance.
• Support muscle recovery and growth for athletes looking to optimize their training results.
• Aid in muscle development for people experiencing age-related muscle loss.
• Improve muscle volume and strength in individuals recovering from injury or surgery.

1. Executive Summary

ACE-031 (Ramatercept) is a recombinant fusion protein engineered to inhibit myostatin, a negative regulator of skeletal muscle growth. The compound consists of the extracellular domain of human activin receptor type IIB (ActRIIB) fused to the Fc portion of human immunoglobulin G1 (IgG1) [4]. By functioning as a soluble "decoy receptor," ACE-031 binds circulating myostatin and related TGF-β superfamily members, preventing them from activating the natural membrane-bound ActRIIB receptor on muscle cells [5].

Originally developed by Acceleron Pharma in collaboration with Shire for treating Duchenne muscular dystrophy (DMD), ACE-031 demonstrated impressive muscle-building efficacy in human clinical trials:

• 3.3% increase in total body lean mass at day 29 (3 mg/kg dose) [6]
• 5.1% increase in thigh muscle volume (MRI-measured) [6]
• Linear dose-response relationship from 0.02 to 3 mg/kg
• 10-15 day half-life enabling once-monthly dosing [6]

However, these promising results were overshadowed by cardiovascular safety concerns. Clinical trials revealed bleeding-related adverse events (epistaxis, telangiectasias, gum bleeding) in both healthy volunteers and DMD patients [7]. Following FDA and Health Canada regulatory review, all studies were terminated in 2011, and in May 2013, the development program was permanently discontinued [1].

Athletic Doping Context: Despite discontinuation, ACE-031 remains available through illicit research chemical suppliers and has been detected in anti-doping testing [3]. WADA prohibits ACE-031 under Section S4.3 (Metabolic Modulators) due to its muscle-enhancing properties [8].

2. Chemical Structure & Composition

Molecular Profile

Chemical Formula: C₃₄₁₈H₅₁₈₈N₉₂₈O₁₀₆₂S₃₈ (homodimeric form) Molecular Weight: 77,489.82 g/mol [9] Protein Length: 343 amino acids per monomer Structure: Homodimeric fusion protein

Protein Domain Architecture

ACE-031 is engineered from two functional protein domains:

1. ActRIIB Extracellular Domain (N-terminal)

• Amino Acids: ~115 residues from human activin receptor type IIB
• Function: Ligand-binding domain for myostatin, GDF-11, activins, and related TGF-β superfamily members
• Binding Affinity: High avidity for myostatin (K_D in nanomolar range)

2. IgG1 Fc Domain (C-terminal)

• Composition: Hinge region + CH2 + CH3 constant domains of human immunoglobulin G1
• Function:
  • Promotes homodimerization (two ActRIIB domains per molecule)
  • Extends plasma half-life via FcRn recycling
  • Provides structural stability

Post-Translational Modifications

• Glycosylation: Contains three N-glycosylation sites [10]
• Disulfide Bonds: Multiple intra-chain and inter-chain disulfide bridges stabilize structure
• Homodimer Formation: Two fusion protein monomers linked via Fc domain

Mechanism of Homodimerization

The Fc domain spontaneously forms a homodimer through disulfide bonding and non-covalent interactions, creating a molecule with:

• Two ActRIIB binding domains (bivalent ligand binding)
• Enhanced ligand sequestration compared to monomeric receptors
• Increased plasma stability and reduced renal clearance

Chemical Properties

• Solubility: High aqueous solubility (typical for Fc-fusion proteins)
• Stability: Stable when lyophilized; sensitive to freeze-thaw cycles in solution
• pH Stability: Optimal stability at physiological pH (7.0–7.4)

3. Mechanism of Action

Myostatin Signaling Pathway (Normal Physiology)

To understand ACE-031's mechanism, we must first review myostatin (GDF-8) biology:

Myostatin is a member of the TGF-β superfamily that negatively regulates skeletal muscle mass [5]. Under normal conditions:

1. Myostatin Secretion: Muscle cells secrete myostatin as an inactive precursor
2. Proteolytic Activation: Extracellular proteases cleave myostatin to its active form
3. Receptor Binding: Active myostatin binds to activin receptor type IIB (ActRIIB) on muscle cell membranes
4. Signaling Cascade: ActRIIB recruits type I receptors (ALK4/ALK5), activating SMAD2/3 transcription factors
5. Gene Regulation: SMAD signaling inhibits muscle protein synthesis and myoblast differentiation
6. Result: Muscle growth is suppressed

Genetic Validation: Myostatin knockout mice develop muscle hypertrophy ~2× normal size. Humans with myostatin mutations exhibit extreme muscularity [5].

ACE-031 Mechanism: Soluble Decoy Receptor

ACE-031 functions as a ligand trap or decoy receptor [4]:

Step 1: Ligand Sequestration

• ACE-031 circulates in the bloodstream as a soluble protein
• The ActRIIB extracellular domain binds myostatin and related ligands before they can reach muscle cell receptors
• High-affinity binding (nanomolar K_D) sequesters ligands away from target tissues

Step 2: Prevention of Receptor Activation

• By capturing myostatin, ACE-031 prevents activation of endogenous membrane-bound ActRIIB receptors
• No SMAD2/3 signaling occurs
• Muscle cells escape myostatin-mediated growth inhibition

Step 3: Anabolic Muscle Response

• Without myostatin signaling, muscle protein synthesis increases
• Myoblast proliferation and differentiation proceed unchecked
• Satellite cell activation enhances muscle repair and hypertrophy

Ligand Specificity

ACE-031 does not exclusively bind myostatin. The ActRIIB receptor recognizes multiple TGF-β superfamily ligands [11]:

Primary Targets:

• Myostatin (GDF-8): Primary inhibitory signal for skeletal muscle
• GDF-11: Related to myostatin; regulates aging and tissue homeostasis
• Activin A/B: Involved in reproductive function, inflammation, and metabolism

Physiological Consequence: By inhibiting activins and GDF-11 in addition to myostatin, ACE-031 may produce broader systemic effects beyond muscle growth. This off-target activity likely contributes to adverse events (telangiectasias, bleeding) [7].

Bone and Adipose Effects

ActRIIB inhibition also influences:

Bone Density:

• Activin signaling regulates osteoblast/osteoclast balance
• ACE-031 may increase bone formation (beneficial for DMD patients prone to fractures)

Fat Mass:

• ActRIIB signaling may influence adipocyte differentiation
• Clinical trials showed modest reductions in fat mass alongside muscle gains [12]

Comparison to Other Myostatin Inhibitors

Note: ACE-031's Fc-fusion design extends half-life but also increases systemic exposure, potentially explaining cardiovascular adverse events not seen with more localized approaches (e.g., ACE-083).

4. Pharmacokinetics

Absorption

Route: Subcutaneous injection (all clinical trials used SC administration)

Bioavailability: A related molecule, ACE-011 (sotatercept, ActRIIA-Fc), demonstrated essentially complete absorption following subcutaneous dosing [13]. ACE-031 likely exhibits similar high bioavailability given structural similarity (both are Fc-fusion proteins).

Time to Peak (T_max): Not explicitly reported, but typical Fc-fusion proteins reach peak plasma levels within 2–7 days post-SC injection.

Distribution

Volume of Distribution (V_d): Expected to be similar to serum volume (~5 L) due to large molecular size (77.5 kDa) limiting extravascular distribution.

Tissue Penetration:

• Limited penetration into peripheral tissues due to large molecular weight
• Primarily confined to vascular and interstitial compartments
• May reach muscle via capillary leakage or inflammation-induced vascular permeability

Protein Binding: As an IgG1-Fc fusion, ACE-031 likely binds to FcRn (neonatal Fc receptor) in endothelial cells, protecting it from lysosomal degradation and extending half-life.

Metabolism

Proteolytic Degradation: Like all protein therapeutics, ACE-031 is metabolized via:

1. Reticuloendothelial System: Uptake by macrophages in liver and spleen
2. Proteolysis: Degradation into constituent amino acids via lysosomal enzymes
3. Amino Acid Recycling: Resulting amino acids enter general metabolic pools

FcRn Recycling: The Fc domain binds FcRn at acidic pH (endosomes), returning to cell surface and extending circulation time. This mechanism is responsible for the long half-life characteristic of IgG and IgG-Fc fusions.

Elimination

Half-Life (T_½): 10–15 days in humans [6]

This extended half-life is due to:

• Large molecular size (limited glomerular filtration)
• FcRn-mediated protection from degradation
• Slow receptor-mediated endocytosis

Clearance:

• Mean clearance not explicitly reported in available literature
• Expected to be low (typical IgG clearance: 0.2–0.3 mL/kg/day)

Excretion:

• No renal or hepatic excretion of intact protein (too large for glomerular filtration)
• Final elimination products (amino acids) excreted via normal metabolic pathways

Pharmacokinetic Linearity

Dose Proportionality: ACE-031 exhibits linear pharmacokinetics across the tested dose range (0.02–3 mg/kg):

• AUC (area under curve): Increased proportionally with dose [6]
• C_max (maximum concentration): Increased linearly with dose [6]
• No saturation: No evidence of receptor-mediated clearance saturation at tested doses

Clinical Implication: Predictable dose-response relationship enables precise dosing adjustments.

Pharmacodynamics (PK/PD Relationship)

Muscle Volume Increase:

• Dose-dependent lean mass gains observed
• 3 mg/kg dose: 3.3% increase in total lean mass, 5.1% increase in thigh muscle volume at day 29 [6]
• Smaller doses produced proportionally smaller effects

Onset of Action:

• Measurable lean mass increases detected as early as day 15 in Phase I trials
• Maximal effects observed at day 29 post-dose in single-dose studies

Duration of Effect:

• Given 10–15 day half-life, muscle-building effects likely persist for 4–6 weeks post-injection
• This supported the once-monthly dosing regimen used in DMD Phase II trials [7]

5. Dosing Protocols

ACE-031 is NOT approved for human use and was permanently discontinued in 2013 due to safety concerns [1]. The dosing information below is provided solely for research reference and historical context. Any use of ACE-031 outside controlled research environments is illegal, dangerous, and strongly discouraged.

Clinical Trial Dosing (Historical Data)

Phase I: Healthy Postmenopausal Women [6]

Study Design: Randomized, double-blind, placebo-controlled, single ascending dose

Participants: 48 healthy postmenopausal women Route: Subcutaneous injection Dose Range: 0.02, 0.05, 0.1, 0.25, 0.5, 1.0, 2.0, 3.0 mg/kg Frequency: Single dose (no repeat dosing in Phase I)

Key Findings:

Safety: Generally well-tolerated; adverse events included injection site erythema. No serious adverse events reported in Phase I [6].

Phase II: Duchenne Muscular Dystrophy Boys [7]

Study Design: Randomized, double-blind, placebo-controlled

Participants: Ambulatory boys aged 5–12 years with DMD Route: Subcutaneous injection Frequency: Once every 4 weeks for 12 weeks (3 total doses) Dose: Not explicitly stated in available abstracts (likely 1–3 mg/kg range based on Phase I data)

Results:

• Muscle volume: Increased by 3.5% in ACE-031 group vs. 0.2% in placebo at day 29 [14]
• Functional outcomes: Data limited due to early termination

Safety Concerns Leading to Discontinuation:

• Epistaxis (nosebleeds): Minor but recurrent
• Telangiectasias: Small dilated blood vessels near skin surface
• Gum bleeding: Occasional reports

These bleeding events, while individually mild, were deemed concerning enough by FDA and Health Canada to warrant study termination [7].

Illicit / Research Chemical Dosing (Anecdotal, Not Evidence-Based)

Despite discontinuation, ACE-031 is available through unregulated research chemical suppliers [3]. Anecdotal reports from bodybuilding forums suggest the following protocols:

Typical Anecdotal Dose:

• 1–3 mg/kg subcutaneous, once every 2–4 weeks
• For a 90 kg (198 lb) individual: 90–270 mg per injection

Example Cycle:

• Week 1: 200 mg SC
• Week 3: 200 mg SC
• Week 5: 200 mg SC
• Total: 3 injections over 6 weeks

Warning: These protocols are entirely unsupported by clinical evidence and carry unknown risks, particularly given the bleeding complications identified in clinical trials.

Body Weight-Based Dosing (Clinical Trial Extrapolation)

Based on Phase I data, weight-based dosing would follow:

Note: 3 mg/kg produced maximum muscle gains but is also closest to doses associated with adverse events. No established "safe" dose exists.

Sex-Specific Considerations

No published data differentiates ACE-031 response by sex.

Theoretical Considerations:

• Testosterone Interaction: Myostatin inhibition may synergize with androgens (males may experience greater muscle response)
• Activin Signaling: Activins regulate menstrual cycle and ovarian function; ACE-031's inhibition of activins could theoretically disrupt female reproductive hormones
• Cardiovascular Risk: Telangiectasias and bleeding may be sex-independent

Recommendation: Insufficient data to recommend sex-specific dosing. Women of childbearing potential should avoid due to unknown effects on reproduction.

Age-Related Modifications

Clinical trials enrolled:

• Phase I: Postmenopausal women (>50 years)
• Phase II: Boys aged 5–12 years with DMD

Young Adults (18–30):

• No clinical data
• Theoretical: May require lower doses due to higher baseline muscle protein synthesis rates

Middle Age (30–50):

• No clinical data
• Standard clinical trial doses (1–3 mg/kg) likely applicable

Older Adults (50+):

• Phase I enrolled this population; doses up to 3 mg/kg tolerated
• Age-related vascular changes may increase bleeding risk

Pediatric:

• Phase II enrolled DMD boys; doses not publicly specified
• Use in healthy children never tested and not recommended

Activity Level and Goals

No data supports activity-specific dosing adjustments.

Theoretical Considerations:

• Athletes: May seek higher doses for maximum muscle gain (2–3 mg/kg range)
• Sedentary DMD Patients: Original target population; doses designed to preserve muscle in non-exercising individuals
• Resistance Training: Myostatin inhibition + mechanical load may produce synergistic hypertrophy

Reconstitution (If Using Research Chemical)

ACE-031 is supplied as lyophilized powder and requires reconstitution before injection:

1. Solvent: Use bacteriostatic water (0.9% benzyl alcohol)
2. Concentration Example:
   • 1 mg vial + 1 mL bacteriostatic water = 1 mg/mL solution
   • For 200 mg dose (90 kg × 2.2 mg/kg), you would need 200 vials (impractical)
   • Realistic vial sizes: Research suppliers offer 1 mg, 2 mg, or 5 mg vials
3. Mixing: Add solvent slowly to vial wall; gently swirl (do not shake)
4. Storage: Refrigerate reconstituted solution at 2–8°C; use within 14–28 days

Injection Technique:

• Use insulin syringe (27–30 gauge, 0.5–1 inch needle)
• Subcutaneous injection into abdomen, thigh, or upper arm
• Rotate injection sites to prevent lipohypertrophy

6. Clinical Research & Evidence

Human Clinical Trials

Phase I: Single Ascending Dose in Healthy Women [6]

Citation: Attie KM, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47(3):416-423.

Study Design:

• Type: Randomized, double-blind, placebo-controlled
• Participants: 48 healthy postmenopausal women
• Dose Range: 0.02–3.0 mg/kg subcutaneous (8 dose cohorts)
• Primary Endpoint: Safety and pharmacokinetics
• Secondary Endpoints: Lean mass (DXA), thigh muscle volume (MRI)

Results:

• Pharmacokinetics: T_½ = 10–15 days, linear PK
• Muscle Outcomes:
  • 3 mg/kg dose: +3.3% lean mass (p=0.03), +5.1% thigh muscle (p=0.03) at day 29
  • Lower doses showed dose-dependent trends
• Safety: Generally well-tolerated; injection site reactions most common
• Serious Adverse Events: None

Quality: High-quality Phase I trial; rigorous design and methodology.

Phase II: Duchenne Muscular Dystrophy [7]

Citation: Campbell C, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55(4):458-464.

Study Design:

• Type: Randomized, double-blind, placebo-controlled
• Participants: Ambulatory boys (5–12 years) with DMD
• Dosing: Once every 4 weeks for 12 weeks (3 doses total)
• Primary Endpoint: Muscle volume by MRI
• Secondary Endpoints: Functional tests (6-minute walk, timed function tests)

Results:

• Muscle Volume: +3.5% in ACE-031 group vs. +0.2% in placebo at day 29 [14]
• Functional Outcomes: Data limited due to early termination

Termination Reason:

• Bleeding Adverse Events: Nosebleeds, gum bleeding, telangiectasias observed in multiple participants [7]
• FDA/Health Canada Review: Led to immediate study suspension and eventual discontinuation [1]

Quality: Well-designed RCT, but limited conclusions due to premature termination.

Animal Research

Myostatin Knockout Models:

• Mice lacking functional myostatin exhibit ~2× muscle mass compared to wild-type [5]
• Demonstrates proof-of-concept for myostatin inhibition as muscle-building strategy

ActRIIB-Fc Preclinical Studies:

• Similar fusion proteins tested in rodents show dose-dependent muscle hypertrophy
• Bone density improvements noted in some models
• Safety profiles in animals did not predict human bleeding complications

Research Quality Assessment

Conclusion: High-quality evidence for short-term efficacy (muscle building) but insufficient long-term safety data led to discontinuation.

Clinical Trials Registry

ClinicalTrials.gov Identifiers:

• NCT01099761: Study of ACE-031 in Subjects with Duchenne Muscular Dystrophy [15]
• NCT01239758: Extension Study of ACE-031 in DMD [16]

Status: Both studies terminated in 2011.

Knowledge Gaps

1. Long-Term Safety: Unknown effects beyond 12 weeks
2. Cardiovascular Mechanism: Why bleeding/telangiectasias occur is unclear
3. Functional Outcomes: Did muscle gains translate to improved strength or function in DMD?
4. Pediatric vs. Adult Response: Different age groups may respond differently
5. Combination Therapies: Interaction with corticosteroids (standard DMD treatment) unknown

7. Safety Profile

Common Side Effects

Phase I (Healthy Volunteers) [6]

Note: In initial Phase I trials, no serious or severe adverse events were reported at any dose level [6].

Phase II (DMD Patients) [7]

More concerning adverse events emerged in repeat-dosing DMD trials:

Critical Finding: While individually mild, the pattern of bleeding-related events raised concerns about underlying vascular pathology [1].

Serious Adverse Events

Vascular Complications:

The bleeding events (epistaxis, telangiectasias, gum bleeding) were deemed potentially serious due to:

1. Recurrence: Multiple participants affected
2. Unknown Mechanism: ActRIIB inhibition's role in vascular integrity unclear
3. Risk of Progression: Concern that minor bleeding could escalate to serious hemorrhage with chronic use

FDA/Health Canada Review Outcome:

"By themselves, the minor bleeding events and dilated blood vessels were not considered to be a serious safety concern for study subjects, but the regulatory review led to termination nonetheless." [2]

Regulatory Interpretation: The pattern of vascular events, combined with uncertain long-term consequences, warranted halting development despite the mild nature of individual events.

Contraindications

Based on trial findings and pharmacology:

Absolute Contraindications

1. Bleeding Disorders: Hemophilia, von Willebrand disease, thrombocytopenia
2. Anticoagulant Therapy: Warfarin, heparin, DOACs (bleeding risk multiplied)
3. Vascular Abnormalities: Known telangiectasias, hereditary hemorrhagic telangiectasia (HHT)
4. Pregnancy: Unknown effects on fetal vascular development
5. Severe Cardiovascular Disease: Uncontrolled hypertension, recent stroke, aneurysm

Relative Contraindications

• Liver Disease: May impair protein metabolism
• Kidney Disease: Altered drug clearance (though minimal renal elimination expected)
• Recent Surgery: Increased bleeding risk
• Aspirin/NSAID Use: Additive anti-platelet effects

Drug Interactions

No formal drug interaction studies conducted (development terminated before Phase III/IV).

Theoretical Interactions:

• Anticoagulants: Additive bleeding risk (warfarin, heparin, DOACs)
• Antiplatelet Agents: Aspirin, clopidogrel may increase bleeding
• Corticosteroids: Standard DMD treatment; interaction profile unknown
• Anabolic Steroids: Synergistic muscle-building; cardiovascular risk unclear

Long-Term Safety

Unknown. Longest exposure in clinical trials was 12 weeks (Phase II DMD study). Questions remaining:

1. Chronic Bleeding Risk: Would vascular events worsen with prolonged use?
2. Bone Effects: Long-term ActRIIB inhibition might alter bone remodeling
3. Reproductive Function: Activin signaling regulates fertility; chronic inhibition effects unknown
4. Cancer Risk: TGF-β superfamily plays role in tumor suppression; theoretical concern

Lack of Data = Unacceptable Risk for approval.

Special Populations

Pediatric (DMD Patients)

• Phase II enrolled boys 5–12 years
• Bleeding events observed despite careful monitoring
• Not recommended outside controlled trials (which no longer exist)

Geriatric

• Phase I enrolled postmenopausal women (≥50 years)
• Age-related vascular fragility may increase telangiectasia risk
• Not recommended due to discontinued status

Pregnancy / Lactation

• Contraindicated: No data; potential fetal vascular development harm
• Category X (if classified): Should not be used

Renal/Hepatic Impairment

• No specific studies conducted
• Protein therapeutics generally safe in renal impairment (minimal renal clearance)
• Hepatic impairment may alter degradation but unlikely to be major concern

8. Administration & Practical Application

Routes of Administration

Subcutaneous Injection (ONLY Validated Route)

All clinical trials used subcutaneous (SC) administration [6]. No evidence supports:

• Intramuscular injection (IM)
• Intravenous injection (IV)
• Oral administration (protein would be digested)

Reconstitution Protocol

ACE-031 is supplied as lyophilized (freeze-dried) powder requiring reconstitution:

Step-by-Step Reconstitution:

1. Supplies Needed:

   • ACE-031 lyophilized vial (1 mg, 2 mg, or 5 mg)
   • Bacteriostatic water (0.9% benzyl alcohol)
   • Sterile syringe and needle (21–22 gauge for reconstitution)
   • Alcohol swabs

2. Reconstitution:

   • Wipe vial stoppers with alcohol
   • Draw appropriate volume of bacteriostatic water:
     • 1 mg vial + 1 mL = 1 mg/mL
     • 2 mg vial + 2 mL = 1 mg/mL
     • 5 mg vial + 5 mL = 1 mg/mL
   • Inject solvent slowly down the vial wall (not directly onto powder)
   • Gently swirl to dissolve (DO NOT shake vigorously; proteins are fragile)
   • Solution should be clear and colorless

3. Storage Post-Reconstitution:

   • Temperature: 2–8°C (refrigerator)
   • Duration: Use within 14–28 days (preservative limits bacterial growth)
   • Protect from Light: Store in original vial or wrap in foil

Injection Technique

Site Selection:

• Abdomen (avoid 2 inches around navel)
• Anterior thigh
• Upper arm (deltoid region, if assisted)

Procedure:

1. Clean injection site with alcohol swab
2. Pinch skin to create subcutaneous "tent"
3. Insert needle at 45–90 degree angle (depending on body fat)
4. Aspirate gently (if blood appears, withdraw and select new site)
5. Inject slowly over 5–10 seconds
6. Withdraw needle and apply gentle pressure (do not massage)

Needle Gauge:

• 27–30 gauge, 0.5–1 inch length (insulin syringe ideal)

Injection Volume:

• For large doses (e.g., 200 mg), multiple injections may be required:
  • Maximum SC volume per site: 1–2 mL
  • Divide dose across 2–4 sites if necessary

Site Rotation: Use different sites for each injection to prevent lipohypertrophy or tissue irritation.

Timing Considerations

Frequency: Based on 10–15 day half-life, dosing intervals include:

• Once every 2 weeks: Maintains more stable drug levels
• Once every 4 weeks: Used in Phase II DMD trials [7]
• Single dose: Phase I protocol [6]

Time of Day:

• No specific recommendations (systemic protein therapeutic, not circadian-dependent)
• Morning or evening dosing equally acceptable

Meal Timing:

• Not applicable (injection bypasses GI tract)

Exercise Timing:

• No specific guidance
• Theoretical: Dosing before resistance training block may maximize hypertrophic response

Monitoring & Lab Work

Baseline Labs (Pre-Use):

• Complete blood count (CBC) – assess baseline platelet count
• Coagulation panel (PT/INR, aPTT) – identify bleeding disorders
• Comprehensive metabolic panel (CMP) – liver/kidney function
• Lipid panel
• Testosterone (males) – myostatin inhibition may alter hormone levels

Follow-Up Labs (Every 4 Weeks During Use):

• CBC with Platelet Count: Monitor for thrombocytopenia
• Coagulation Studies: Detect clotting abnormalities
• Liver Enzymes: AST/ALT (unlikely to be affected but prudent to monitor)

Clinical Monitoring:

• Nosebleeds: Frequency and severity
• Skin Exam: Look for telangiectasias (spider veins)
• Gum Bleeding: During brushing or spontaneous
• Muscle Volume: DXA or MRI (research setting)

Red Flags Requiring Immediate Discontinuation:

• Recurrent epistaxis (>1–2 episodes)
• Development of telangiectasias
• Any spontaneous bleeding (GI, urinary, etc.)
• Severe headache (potential intracranial bleed)

9. Storage & Stability

Lyophilized Powder Storage

Optimal Conditions:

• Temperature: -20°C to -80°C (freezer storage) for long-term
• Short-Term: 2–8°C (refrigerator) acceptable for up to 6 months
• Room Temperature: Stable for brief periods (days to weeks) but not recommended
• Light Protection: Store in original amber vial or foil-wrapped
• Moisture: Desiccant packets recommended; protein powders hygroscopic

Shelf Life:

• Frozen (-20°C or colder): 2–3 years (manufacturer data needed for specifics)
• Refrigerated (2–8°C): 6–12 months
• Room Temperature: Not recommended for long-term storage

Visual Inspection:

• Lyophilized powder should be white to off-white cake or powder
• Discoloration (yellowing, browning) indicates degradation

Reconstituted Solution Storage

Critical Requirements:

• Temperature: 2–8°C (refrigerator) – DO NOT FREEZE reconstituted solution
• Container: Sterile glass vial with rubber stopper
• Duration: Use within 14–28 days when using bacteriostatic water
• Without Preservative: If reconstituted with sterile water (no bacteriostatic agent), use within 72 hours

Signs of Degradation:

• Cloudiness: Protein aggregation or bacterial contamination
• Particulates: Visible floating particles
• Color Change: Should remain clear/colorless
• pH Shift: If pH indicator present, color change may signal instability

Discard If:

• Visible particulates present
• Solution appears cloudy or discolored
• Expired beyond 28-day window
• Vial integrity compromised (crack, contamination)

Handling Precautions

1. Avoid Freeze-Thaw Cycles:

   • Each freeze-thaw cycle degrades protein structure
   • Aliquot reconstituted solution into single-use vials if frequent dosing

2. Sterile Technique:

   • Always use alcohol swabs on vial stoppers before needle insertion
   • Never reuse needles or syringes
   • Minimize air exposure to reconstituted solution

3. Minimize Agitation:

   • Proteins denature with excessive shaking
   • Gently swirl to mix; never vortex or shake vigorously

4. Transport:

   • Use insulated cooler with ice packs if transporting reconstituted solution
   • Maintain 2–8°C during transport

Disposal

Needles/Sharps:

• Use FDA-cleared sharps disposal container
• Never dispose of needles in household trash

Expired/Degraded Product:

• Follow local pharmaceutical waste disposal regulations
• Do not flush down toilet or pour down drain
• Return to pharmacy or hazardous waste collection if available

11. Product Cross-Reference

Core Peptides Product Information

Product Available: YES [9]

SKU: P-ACE031-1

Specifications:

• Form: Lyophilized powder
• Vial Size: 1 mg per vial
• Purity: Claimed >99%
• Molecular Formula: C₃₄₁₈H₅₁₈₈N₉₂₈O₁₀₆₂S₃₈
• Molecular Weight: 77,489.82 g/mol [9]

Pricing:

• Single Vial: $173.00
• Bulk Discounts:
  • 5–8 units: $164.35 (5% off)
  • 9+ units: $155.70 (10% off)
• Free Shipping: Orders over $200

Quality Documentation:

• Certificate of Analysis (COA)
• HPLC testing
• Mass spectrometry

Note: Core Peptides explicitly states:

"This peptide is marketed strictly for laboratory and research applications and explicitly prohibited for human or animal consumption."

Chemical Equivalence Validation

Cross-Reference with Epiq Aminos ACE-031:

Recommendation: When purchasing ACE-031 from any source, demand:

1. Certificate of Analysis (COA) from independent third-party lab
2. HPLC Chromatogram showing purity profile
3. Mass Spectrometry confirming molecular weight
4. Endotoxin Testing (for injectable use)

Price Comparison

Market Pricing (2025 Estimates):

Interpretation:

• Core Peptides pricing is on the higher end, potentially reflecting quality assurance
• Epiq Aminos offers competitive pricing
• Beware of suspiciously cheap products (likely underdosed or counterfeit)

Dose Cost Calculation (Example: 200 mg dose for 90 kg individual):

• Core Peptides: 200 mg × $173/mg = $34,600 per dose (impractical)
• Epiq Aminos: 200 mg × $109/mg = $21,800 per dose (still impractical)

Reality Check: At these prices, even a single clinical-dose injection is prohibitively expensive for non-research use. This likely explains why ACE-031 is less commonly used in illicit performance enhancement compared to cheaper compounds (e.g., peptides like BPC-157, TB-500).

12. References & Citations

Primary Research Articles

1. MDA Quest. UPDATE: ACE-031 Clinical Trials in Duchenne MD. 2013.

2. Muscle and Brawn. ACE-031 Peptide: Everything You Need For Increased Muscle Growth. 2024.

3. Reichel C, et al. Gel Electrophoretic Detection of Black Market ACE-031. Drug Testing and Analysis. 2025.

4. ChemicalBook. ACE 031 Chemical Properties. 2024.

5. PeptideWiki. ACE-031 Mechanism and Research. 2024.

6. Attie KM, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47(3):416-423.

7. Campbell C, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55(4):458-464.

8. Reichel C, et al. Gel Electrophoretic Detection of Black Market ACE-031. Drug Test Anal. 2025.

9. Core Peptides. ACE-031 1mg Product Page. 2025.

10. Attie KM, et al. A single ascending-dose study. Muscle Nerve. 2013.

11. Evolutionary.org. Ace-031 Myostatin Inhibitor. 2024.

12. Genemedics. ACE-031 Overview. 2024.

13. Sherman ML, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009;24(4):744-52.

14. BiotechPeptides. Comprehensive Research on ACE-031 Peptide. 2024.

15. ClinicalTrials.gov. Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy. NCT01099761.

16. ClinicalTrials.gov. Extension Study of ACE-031 in DMD. NCT01239758.

17. BioSpace. Acceleron Pharma Receives FDA Orphan Designation for ACE-031. 2010.

Regulatory Documents

• WADA Prohibited List 2024 (S4.3 Metabolic Modulators)
• FDA Orphan Drug Designations Database

Chemical Databases

• CAS Registry Number: 1621169-52-5
• ChemicalBook: ACE 031
• AbMole BioScience: ACE-031

13. Goal Archetype Integration

Primary Goal Archetypes

ACE-031's mechanism of action positions it within specific performance and therapeutic goal categories. Understanding these archetypes helps contextualize the compound's intended applications and limitations.

Archetype 1: Muscle Hypertrophy & Mass Acquisition

Mechanism Alignment:

• Myostatin Inhibition: ACE-031 directly addresses the most potent endogenous inhibitor of muscle growth
• TGF-β Pathway Modulation: Blocks SMAD2/3 signaling cascade that normally suppresses protein synthesis
• Satellite Cell Activation: Removal of myostatin inhibition allows enhanced muscle stem cell proliferation

Expected Outcomes (Based on Clinical Data):

• 3–5% lean mass increase within 4 weeks
• 5% thigh muscle volume increase (MRI-measured)
• Enhanced muscle protein synthesis capacity

Synergy Considerations:

• Resistance training may amplify response (mechanical load + reduced catabolic signaling)
• Adequate protein intake essential (substrate for anabolism)
• Sleep optimization supports growth hormone axis

Limitations:

• Gains are modest compared to anabolic steroids (3–5% vs. 10–20%)
• Vascular safety concerns limit practical utility
• Cost-prohibitive for sustained use

Archetype 2: Anti-Sarcopenia / Age-Related Muscle Preservation

Rationale: Sarcopenia (age-related muscle loss) affects 10–16% of adults over 60 years [18]. Myostatin levels may increase with age in women, contributing to accelerated muscle loss [19].

Evidence for Myostatin Inhibition in Aging:

• Anti-myostatin antibody treatment increased muscle mass and strength in aged mice [20]
• Myostatin-null mice showed minimal age-related fiber atrophy compared to wild-type [21]
• Improved insulin sensitivity observed in aged treated mice

Challenges:

• Chronic mTORC1 activation (which myostatin inhibition promotes) may paradoxically accelerate sarcopenia in some contexts [22]
• Age-related vascular fragility increases telangiectasia risk
• No clinical trials in sarcopenic elderly populations completed

Archetype 3: Muscular Dystrophy Therapeutic

Original Development Intent: ACE-031 was designed for Duchenne muscular dystrophy (DMD), where muscle degeneration occurs regardless of exercise capacity [7].

Theoretical Advantages:

• Does not require exercise stimulus (critical for non-ambulatory patients)
• Addresses catabolic pathway independent of dystrophin deficiency
• Long half-life enables monthly dosing (compliance advantage)

Clinical Reality:

• Phase II DMD trial terminated due to bleeding events
• Functional improvements could not be fully assessed before termination
• Alternative myostatin inhibitors (Domagrozumab, Taldefgrobep alfa) now in development

Archetype 4: Athletic Performance Enhancement

Doping Context: Despite discontinued status, ACE-031 is sought for performance enhancement due to its muscle-building efficacy [8].

Potential Applications (Illicit):

• Bodybuilding: Lean mass addition without water retention
• Strength sports: Increased muscle cross-sectional area
• Combat sports: Weight class optimization

Detection and Consequences:

• WADA-prohibited (S4.3 Metabolic Modulators)
• Gel electrophoretic detection methods available [3]
• Detection window: 4–6 weeks post-administration
• Standard doping sanctions apply

Goal-Mechanism Compatibility Matrix

14. Age-Stratified Dosing Considerations

No validated dosing protocols exist for any age group. ACE-031 development was terminated before dose optimization studies could establish age-specific recommendations. The following represents theoretical extrapolation from available pharmacokinetic data and should not be interpreted as clinical guidance.

Pharmacokinetic Considerations by Age

Young Adults (18–30 years)

Physiological Context:

• Peak muscle protein synthesis capacity
• Optimal hormone profiles (testosterone, IGF-1)
• Robust vascular integrity

Theoretical Dosing Considerations:

• May require lower doses due to higher baseline anabolic capacity
• Myostatin inhibition may provide less additional benefit when endogenous anabolic signals are already strong
• Lower cardiovascular risk but not zero

Extrapolated Dose Range: 0.5–1.5 mg/kg every 4 weeks (conservative approach)

Middle Age (30–50 years)

Physiological Context:

• Declining testosterone (1–2% annual decrease in men)
• Increasing myostatin expression in some individuals
• Early vascular changes may be present

Theoretical Dosing Considerations:

• Clinical trial doses (1–3 mg/kg) likely applicable
• May experience greater relative benefit than younger adults
• Cardiovascular screening recommended before any use

Extrapolated Dose Range: 1–2 mg/kg every 4 weeks

Older Adults (50–70 years)

Physiological Context:

• Sarcopenia onset common (especially >60 years)
• Increased myostatin levels documented in older women [19]
• Age-related vascular fragility (increased telangiectasia risk)
• Reduced renal/hepatic clearance may prolong exposure

Theoretical Dosing Considerations:

• Increased caution required due to vascular vulnerability
• Consider extended dosing intervals (every 6–8 weeks) rather than higher doses
• Baseline coagulation studies essential
• Enhanced monitoring for bleeding events

Extrapolated Dose Range: 0.5–1 mg/kg every 6–8 weeks (if used at all)

Elderly (>70 years)

Physiological Context:

• Highest sarcopenia prevalence
• Greatest vascular fragility
• Polypharmacy common (drug interaction risk)
• Impaired healing capacity

Recommendation: NOT RECOMMENDED at any dose

Rationale:

• Vascular adverse events observed in clinical trials likely more severe in this population
• Risk-benefit ratio heavily unfavorable
• Alternative interventions (resistance exercise, protein supplementation, vitamin D) have superior safety profiles

Sex-Stratified Considerations

Males

Age-Related Myostatin Changes:

• Older men may have lower myostatin levels than younger men (contrary to women) [19]
• Testosterone-myostatin inverse relationship: low T associated with elevated myostatin

Implications:

• Men with hypogonadism may derive greater benefit
• Consider testosterone status before myostatin inhibition

Females

Age-Related Myostatin Changes:

• Older women show higher circulating myostatin than younger women [19]
• Higher myostatin associated with higher body fat in elderly women

Implications:

• Postmenopausal women may be ideal candidates theoretically
• Phase I enrolled postmenopausal women specifically [6]
• Unknown effects on residual reproductive hormones/activin signaling

Pregnancy/Childbearing Potential: Absolute contraindication (activin signaling critical for reproduction)

Weight-Based Dosing by Age Group

15. Drug Interactions

No formal drug interaction studies were conducted before ACE-031 development termination. All interactions listed below are theoretical based on pharmacological mechanisms and should be considered preliminary.

High-Risk Interactions (Avoid Combination)

Anticoagulants

Recommendation: Absolute contraindication – ACE-031 caused bleeding events without anticoagulants; combination dramatically increases risk.

Antiplatelet Agents

Recommendation: Avoid combination or use with extreme caution and enhanced monitoring.

NSAIDs

Recommendation: Minimize NSAID use; prefer acetaminophen for analgesia if needed.

Moderate-Risk Interactions (Use with Caution)

Corticosteroids

Recommendation: If corticosteroid use is medically necessary, consider that anti-catabolic benefits may be partially offset.

Anabolic Agents

Research Context:

• Myostatin and testosterone are inversely related; low testosterone increases myostatin [23]
• Blocking myostatin while enhancing androgen signaling creates dual pathway stimulation
• YK-11 SARM activates follistatin (endogenous myostatin inhibitor) + androgen receptor [24]

Warning: Combination with anabolic agents is entirely experimental with no safety data.

BMP9/BMP10 Modulators

Recommendation: Avoid all combinations affecting BMP9/BMP10/ALK1 pathway.

Low-Risk Interactions (Monitoring Recommended)

Protein Supplements

Vitamins and Minerals

Herbal/Supplement Interactions

16. Bloodwork Impact & Monitoring

Baseline Assessment (Pre-Use)

Essential Labs

Hormone Panel (Optional but Recommended)

Myostatin-Specific Biomarkers (Research Context)

Note: Myostatin assays are not standardized and may show variability between laboratories.

On-Treatment Monitoring

Frequency: Every 2–4 Weeks During Active Use

Clinical Monitoring (Non-Laboratory)

Expected Bloodwork Changes

Beneficial Changes (Based on Mechanism)

Adverse Changes (Based on Clinical Trial Safety Data)

Discontinuation Criteria (Laboratory-Based)

17. Protocol Integration

Integration with Resistance Training

Training Protocol Optimization

Rationale: Myostatin inhibition removes the "brake" on muscle growth, but mechanical stimulus may still be required to maximize hypertrophic response.

Recommended Approach:

Training Variables:

• Frequency: 2–3× per muscle group per week
• Volume: 10–20 sets per muscle group per week
• Intensity: 65–85% 1RM
• Rest: 60–180 seconds between sets
• Progression: 2.5–5% load increase weekly when possible

Nutritional Protocol Integration

Protein Requirements:

Caloric Considerations:

• Mild surplus (+200–300 kcal/day) optimal for muscle gain
• Maintenance calories may still produce recomposition due to myostatin inhibition
• Deficit not recommended – may blunt anabolic response

Meal Timing:

• Protein distributed across 4–5 meals
• 20–40g protein per meal for maximal MPS
• Casein or mixed protein before sleep

Integration with Hormone Optimization

Testosterone Replacement Therapy (TRT)

Theoretical Synergy:

• TRT addresses anabolic pathway (androgen receptor activation)
• ACE-031 addresses catabolic pathway (myostatin inhibition)
• Dual pathway modulation may produce additive or synergistic effects [23]

Protocol Considerations:

Warning: No clinical data supports this combination. Cardiovascular monitoring essential.

Growth Hormone (GH) Axis

IGF-1 Considerations:

• Myostatin inhibition may increase IGF-1 signaling
• GH/IGF-1 and myostatin pathways converge on mTORC1
• Combination with exogenous GH entirely theoretical

Integration with Other Peptides

Peptides with Potential Synergy

Critical Warning: Combinations of multiple experimental agents have zero safety data. Interactions are entirely unknown.

Peptides to Avoid

Cycle Structure Examples

Conservative Research Protocol (Theoretical)

Duration: 8 weeks Goal: Minimize risk while assessing individual response

Post-Cycle:

• Allow 4–6 weeks for complete washout (5 half-lives)
• Repeat comprehensive bloodwork
• Document any persistent effects

Extended Protocol (Higher Risk)

Duration: 12 weeks Note: Exceeds Phase II DMD trial duration where adverse events occurred

Monitoring: Labs every 2 weeks; immediate discontinuation if bleeding events occur.

Warning: This protocol mirrors Phase II dosing that caused adverse events leading to termination.

Discontinuation and Recovery

Planned Discontinuation

Washout Period: 4–6 weeks (5 half-lives)

• Myostatin signaling gradually returns to baseline
• Muscle gains may partially regress without continued resistance training
• No "PCT" (post-cycle therapy) required or validated

Emergency Discontinuation (Adverse Events)

Immediate Steps:

1. Stop all ACE-031 administration
2. Document adverse event (type, severity, timing)
3. Obtain emergency labs (CBC, coagulation panel)
4. Seek medical evaluation if:
   • Bleeding is moderate-severe
   • Telangiectasias are spreading
   • Any neurological symptoms (potential intracranial bleed)
   • GI bleeding suspected (dark stool, hematemesis)

Recovery Monitoring:

• Labs at 1, 2, and 4 weeks post-discontinuation
• Skin examination for telangiectasia resolution
• Document time to adverse event resolution

Conclusion

ACE-031 represents a cautionary tale in drug development: a compound with impressive muscle-building efficacy but unacceptable safety profile. While clinical trials demonstrated statistically significant increases in lean mass and muscle volume, bleeding-related adverse events (epistaxis, telangiectasias, gum bleeding) led to permanent discontinuation in May 2013 [1].

The vascular adverse effects are now understood to result from off-target inhibition of BMP9 and BMP10, critical ligands for maintaining endothelial quiescence and vascular integrity [26]. This mechanism explains why adverse events resembled hereditary hemorrhagic telangiectasia (HHT), a genetic condition caused by mutations in the same signaling pathway.

Despite its discontinued status, ACE-031 remains available through unregulated research chemical markets and continues to be prohibited by WADA due to its performance-enhancing potential [8]. The compound's high cost ($100–$173 per mg) and known cardiovascular risks make it an unattractive option even in illicit contexts.

Key Takeaways:

1. Efficacy: Proven muscle-building effects in human trials (3–5% lean mass gains)
2. Safety: Bleeding complications from BMP9/10 inhibition led to regulatory termination
3. Status: Permanently discontinued; not FDA-approved; WADA-prohibited
4. Availability: Only through unregulated suppliers (quality/safety unknown)
5. Goal Alignment: Strong mechanistic fit for muscle hypertrophy but practical utility severely limited by safety profile
6. Age Considerations: Older adults at higher vascular risk; not recommended >70 years
7. Drug Interactions: Anticoagulants, antiplatelet agents absolutely contraindicated
8. Monitoring: Comprehensive bloodwork and clinical bleeding surveillance essential

Recommendation: ACE-031 should not be used outside registered clinical trials (which no longer exist). The bleeding risks identified in controlled trials are likely magnified in unsupervised use, and no established safe dosing protocol exists. Alternative myostatin inhibitors with improved selectivity (avoiding BMP9/10 inhibition) remain in development and may offer safer options in the future.

Document Version: 1.0 Last Updated: December 23, 2025 Development Status: DISCONTINUED (May 2013) For Historical Research and Educational Purposes Only